Kraig Biocraft Laboratories to Launch Monster Silk(TM) Pilot Production Program
January 22 2013 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or
"Kraig") announced today that it plans on launching its pilot
production program for Monster Silk™, the Company's recombinant
spider silk, in the first or second quarter of 2013.
The program is designed to transition Kraig from laboratory
scale production to commercial. scale production of Monster Silk™.
The Company anticipates launching the pilot program within the next
sixty to ninety days. The initial goals for the pilot
production program are to confirm production scalability and cost
structures for Monster Silk™, as well as to satisfy the demand for
larger scale Monster Silk™ sample requests from textile producers
and product developers.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully
reporting biotechnology company that has achieved a series of
scientific breakthroughs in the area of spider silk technology with
implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "develops," "researching,"
"research," "potential," "could" or other words or phrases of
similar import. Similarly, statements in this release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals should all be considered forward-looking
statements. All such forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and
create commercially-viable products may be affected by the
competitive environment, the Company's financial condition and its
ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing
operations.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security and shall not
constitute an offer, solicitation or sale of any securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024